EMA: First medicine for rare blood cancer

The European Medicines Agency (EMA) has recommended extending the use of Imbruvica (ibrutinib) to include the treatment of patients with Waldenstrӧm’s macroglobulinaemia, a rare blood cell cancer. Imbruvica is the first medicine that is recommended for this disease. The medicine is indicated for adults who have received at least one prior therapy or as a first line treatment for patients unsuitable for chemo-immunotherapy.